Several months ago we decided to let go of 18 patents that we had originally licensed from NanoLogix for use with our Designer Diagnostics test kit technology. We were no longer using these patents and they are not material to Nutra Pharma, so it did not make sense for us to continue paying hefty royalties to NanoLogix. Additionally, this decision allows us to free up additional cash that we can now put towards better use within the Company. Moving forward, we continue to own 11 patents that are important to developing our test kit technology as it applies to human and animal testing as well as environmental testing.

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " A Quick Note about Recent Changes to our Patent Portfolio", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

               

Comments

No comments yet.

RSS feed for comments on this post.

TrackBack URL

Leave a Comment

Name (required)

Email (will not be published) (required)

Website